No Data
No Data
Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting
Reviva Pharmaceuticals: Promising Schizophrenia Treatment Drives Buy Rating
Express News | Reviva Pharmaceuticals Holdings Inc : Benchmark Cuts Target Price to $14 From $17
Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)
10-K: FY2024 Annual Report
12 Health Care Stocks Moving In Tuesday's Intraday Session